Key facts
- This page summarizes Charles Silberstein's Form 4 filing for Applied Therapeutics Inc. (APLT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Jan 2022, 17:45.
Charles Silberstein - 07 Jan 2022 Form 4 Insider Report for Applied Therapeutics Inc. (APLT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- APLT
- Reported as of
- 07 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2022, 17:45:55 UTC
- Prior SEC filing
- 11 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shoshana Shendelman as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Charles Silberstein filed Form 4 for Applied Therapeutics Inc. (APLT) on 11 Jan 2022.
Change
- Previous filing in this sequence was filed on 11 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +47,900
- Change %
- +35%
- Price
- $0.000000
- Shares after
- 183,603
- Date
- 07 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLT
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +32,000
- Change %
- Price
- $0.000000
- Shares after
- 32,000
- Date
- 07 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,000
- Exercise price
- $4.17
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on January 7, 2023, and one-twelfth (1/12th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each quarter thereafter, subject to the Reporting Person continuing to provide services through each such date.
Footnote F2
Consists of compensatory Options granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on January 7, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.